[HTML][HTML] Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the …
P Wiland, S Jeka, E Dokoupilová, J Brandt-Jürgens… - BioDrugs, 2020 - Springer
Background Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar
with similar efficacy and comparable safety and immunogenicity to reference adalimumab …
with similar efficacy and comparable safety and immunogenicity to reference adalimumab …
[HTML][HTML] Entwicklung von Qualitätsstandards für Patient* innen mit axialer Spondyloarthritis zum Einsatz in Deutschland
…, X Baraliakos, F Behrens, J Brandt-Jürgens… - Zeitschrift für …, 2022 - Springer
Qualitätsstandards (QS) sind messbare Konstrukte, die helfen sollen, Versorgungslücken
quantitativ zu erfassen, um langfristig die Versorgungsqualität zu verbessern. Die Assessment …
quantitativ zu erfassen, um langfristig die Versorgungsqualität zu verbessern. Die Assessment …
Sensitivity and Specificity of Autoantibodies Against CD 74 in Nonradiographic Axial Spondyloarthritis
…, B Bannert, K Becker, J Brandt‐Jürgens… - Arthritis & …, 2019 - Wiley Online Library
Objective Autoantibodies against CD 74 (anti‐ CD 74) are associated with ankylosing spondylitis
( AS ). The present multicenter study, the International Spondyloarthritis Autoantibody (…
( AS ). The present multicenter study, the International Spondyloarthritis Autoantibody (…
[HTML][HTML] Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data …
…, M Romanelli, PD Ghislain, J Brandt-Jürgens… - Advances in …, 2020 - Springer
Introduction Secukinumab, a fully human monoclonal antibody that directly inhibits
interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (…
interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (…
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled …
…, E Herrmann, J Brandt-Jürgens… - The Lancet …, 2023 - thelancet.com
Background The role of methotrexate in combination with biological agents in patients with
psoriatic arthritis remains unclear. The MUST phase 3b trial aimed to compare the efficacy of …
psoriatic arthritis remains unclear. The MUST phase 3b trial aimed to compare the efficacy of …
Clinical relevance of axial radiographic damage in axial spondyloarthritis: evaluation of functional consequences by an objective electronic device
…, M Kabelitz, U Lange, J Brandt-Jürgens… - The Journal of …, 2023 - jrheum.org
Objective Axial spondyloarthritis (axSpA) is associated with decreased function and mobility
of patients as a result of inflammation and radiographic damage. The Epionics SPINE …
of patients as a result of inflammation and radiographic damage. The Epionics SPINE …
Successful evaluation of spinal mobility measurements with the Epionics SPINE device in patients with axial spondyloarthritis compared to controls
…, I Schwarze, U Lange, J Brandt-Jürgens… - The Journal of …, 2022 - jrheum.org
Objective Epionics SPINE (ES), a novel device that measures spinal movements using
electronic sensors including range of motion (RoM) and speed (range of kinematics [RoK]), has …
electronic sensors including range of motion (RoM) and speed (range of kinematics [RoK]), has …
[HTML][HTML] Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in …
…, K Rockwitz, J Brandt-Jürgens… - The open …, 2010 - ncbi.nlm.nih.gov
Objectives: To determine preference, satisfaction, usability and local tolerability by patients,
physicians and study nurses of two subcutaneously administered methotrexate (MTX) …
physicians and study nurses of two subcutaneously administered methotrexate (MTX) …
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
…, S Osiek, A Knothe, G Hoese, J Brandt-Jürgens… - RMD open, 2023 - rmdopen.bmj.com
Objective To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least
double-vaccinated patients with inflammatory rheumatic diseases (IRDs). Methods Data from …
double-vaccinated patients with inflammatory rheumatic diseases (IRDs). Methods Data from …
Global functioning in axial spondyloarthritis is stronger associated with disease activity and function than with mobility and radiographic damage
…, M Kabelitz, U Lange, J Brandt‐Jürgens… - Arthritis Care & …, 2023 - Wiley Online Library
Objective The ASAS Health Index (ASAS HI) is a validated patient‐reported outcome (PRO)
for global functioning of patients with axial spondyloarthritis (axSpA). The Epionics SPINE (…
for global functioning of patients with axial spondyloarthritis (axSpA). The Epionics SPINE (…